338.91
price up icon8.59%   26.80
pre-market  プレマーケット:  338.98   0.07   +0.02%
loading
前日終値:
$312.11
開ける:
$350
24時間の取引高:
1.23M
Relative Volume:
3.47
時価総額:
$7.52B
収益:
-
当期純損益:
$-518.67M
株価収益率:
-13.49
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+15.12%
1か月 パフォーマンス:
+13.40%
6か月 パフォーマンス:
-0.31%
1年 パフォーマンス:
+30.63%
1日の値動き範囲:
Value
$314.80
$350.00
1週間の範囲:
Value
$286.44
$350.00
52週間の値動き範囲:
Value
$200.63
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1162)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
528
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

MDGL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
338.91 6.93B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
374.98 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
569.90 60.58B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
418.91 54.99B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
674.90 42.25B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
307.23 32.93B 3.81B -644.79M -669.77M -6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-28 アップグレード B. Riley Securities Neutral → Buy
2025-02-27 繰り返されました H.C. Wainwright Buy
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
07:42 AM

Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus

07:42 AM
pulisher
03:57 AM

Madrigal: Q2 Earnings Snapshot - New Haven Register

03:57 AM
pulisher
02:25 AM

Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada

02:25 AM
pulisher
12:38 PM

Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com

12:38 PM
pulisher
12:36 PM

Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks

12:36 PM
pulisher
Aug 05, 2025

Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News

Aug 05, 2025
pulisher
Aug 05, 2025

GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Aug 05, 2025
pulisher
Aug 04, 2025

China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - BioCentury

Aug 04, 2025
pulisher
Aug 04, 2025

How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

Is Madrigal Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with advanced market data - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockHigh-profit trading signals - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Madrigal Pharmaceuticals Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketBuild wealth with reliable stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light - MSN

Aug 03, 2025
pulisher
Aug 03, 2025

What are Madrigal Pharmaceuticals Inc. company’s key revenue driversInvest confidently with market-leading analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Madrigal Pharmaceuticals Inc. stockBuild wealth faster with expert stock selection - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Madrigal Pharmaceuticals Inc. a good long term investmentUnlock your portfolio’s hidden potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Madrigal Pharmaceuticals Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

The week in pharma: action, reaction and insight – week to August 1 - The Pharma Letter

Aug 03, 2025
pulisher
Aug 03, 2025

Published on: 2025-08-03 13:27:37 - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Madrigal Pharmaceuticals Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are analysts’ price targets for Madrigal Pharmaceuticals Inc. in the next 12 monthsExceptional risk-adjusted gains - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Should I hold or sell Madrigal Pharmaceuticals Inc. stock in 2025Access daily stock market expert updates - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

What are the technical indicators suggesting about Madrigal Pharmaceuticals Inc.Market Forecast Opportunities Backed By Experts - Jammu Links News

Aug 01, 2025
pulisher
Jul 31, 2025

Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term (MDGL) - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Madrigal in-pact with CSPC Pharma for obesity drug license - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

Analyzing recovery setups for Madrigal Pharmaceuticals Inc. investorsSwing Trade Entry With Volume Triggers Released - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Non-Alcoholic Steatohepatitis Market Set to Grow - openPR.com

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals Enters into Exclusive Global - GlobeNewswire

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals' Strategic Licensing Deal: A Pivotal Move in the NASH Therapeutics Arms Race - AInvest

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal inks license deal with CSPC Pharma - The Pharma Letter

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal in-pact with CSPC Pharma for GLP-1 candidate license - Seeking Alpha

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal obtains rights to CSPC Pharmaceutical’s SYH-2086 - BioWorld MedTech

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals Signs Global License Agreement - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra - Investing.com Nigeria

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited | MDGL Stock News - GuruFocus

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal Pharmaceuticals Enters Exclusive License Agreement with CSPC for SYH2086 to Enhance MASH Treatment Pipeline - Quiver Quantitative

Jul 30, 2025
pulisher
Jul 30, 2025

Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra By Investing.com - Investing.com South Africa

Jul 30, 2025

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.72
price down icon 0.40%
$37.91
price up icon 0.08%
$111.61
price up icon 0.33%
$29.13
price down icon 0.65%
$111.07
price up icon 0.95%
biotechnology ONC
$307.23
price up icon 0.96%
大文字化:     |  ボリューム (24 時間):